Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MZE001 in healthy volunteers
NCT05249621Phase 1Completed
- Sponsor
- Maze Therapeutics
- Start
- Feb 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Pompe disease comparing MZE001 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at 14 days. Started Feb 2022; status: completed.
02
Drugs
MZE001
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT05249621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249621.